[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349957-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349957-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","validation-of-a-blood-based-autoantibody-test-to-assess-lung-cancer-risk-in-430-mm-pulmonary-nodules-retrospective-pooled-analysis-of-four-cohort-studies","Validation of a blood-based autoantibody test to assess lung cancer risk in 4–30 mm pulmonary nodules - retrospective pooled analysis of four cohort studies","","Aim: validate a blood-based autoantibody test (AAT) as a high-specificity rule-in biomarker for malignancy risk in 4–30 mm indeterminate pulmonary nodules (IPN). Methods: retrospective pooled analysis of four cohorts of adults with 4–30 mm IPN, AAT results, and benign or malignant diagnosis; AAT classified into Moderate Level, High Level, and NSLAD, then used AAT likelihood ratios to update post-test cancer probability. Results: among 1164 patients (35% cancer), Moderate Level sensitivity 16% and specificity 91% (PPV 50%); High Level specificity 96% and PPV 57% (sensitivity 9%), with even higher performance when post-test pCA exceeded 65%. Conclusions: size- and risk-independent high-specificity rule-in performance identifies subsets warranting expedited evaluation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/validation-of-a-blood-based-autoantibody-test-to-assess-lung-cancer-risk-in-430-mm-pulmonary-nodules-retrospective-pooled-analysis-of-four-cohort-studies/349957/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/validation-of-a-blood-based-autoantibody-test-to-assess-lung-cancer-risk-in-430-mm-pulmonary-nodules-retrospective-pooled-analysis-of-four-cohort-studies/349957.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study validate, and for which patients?","Question",{"text":63,"@type":64},"The study validates a blood-based autoantibody test (AAT) for use as a high-specificity rule-in biomarker in adults with 4–30 mm indeterminate pulmonary nodules, across malignancy risk levels.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are AAT results categorized and how is cancer risk updated?",{"text":68,"@type":64},"AAT results are classified into Moderate Level, High Level, and NSLAD. Post-test cancer probability is calculated by applying AAT likelihood ratios to pretest cancer probability.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance did the AAT show overall and at higher post-test risk?",{"text":72,"@type":64},"Overall, Moderate Level results showed sensitivity 16%, specificity 91%, and PPV 50%. When post-test pCA exceeded 65%, specificity was 97% and PPV was 69%, with sensitivity 12%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349957,1790667715,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 7, 831–842  \n[https://doi.org/10.1080/14796694.2026.2626339](https://doi.org/10.1080/14796694.2026.2626339)  \n| RESEARCH ARTICLE   \u003Cbr>Validation of a blood-based autoantibody test to assess lung cancer risk in 4–30 mm pulmonary nodules: a retrospective pooled analysis of four cohort studies\u003Cbr>Trevor J. Pitchera, Kathryn J. Longb, Michael N. Kammerc,d, Sandra Schuldheisze, Bharat Bajantrif, Tammy Gleesong, Dragos Zanchih, Sandeep Bansali, Luke Yuhicoj, Laura J Peekk, James R. Jettl, Viswam S. Nairm * and Gerard A. Silvestrin\u003Cbr>aClinical Development, Biodesix Inc., Louisville, CO, USA; bPulmonary Medicine, Cleveland Clinic, Cleveland, OH, USA; cInformatique, Institut de Recherche en Informatique de Toulouse, Université Toulouse Capitole, Toulouse, France; dRadiomics, Biodesix Inc., Louisville, CO, USA; eThe Lung and Sleep Disorder Institute, Somerset, KY, USA; fParkview Research Center, Ft Wayne, IN, USA; gSouthcoast Health Thoracic Surgery, Fairhaven, MA, USA; hPulmonary & Sleep of Tampa Bay, Tampa, FL, USA; iPulmonary, Critical Care Medicine, Penn Highlands Healthcare, Dubois, PA, USA; jWhite-Wilson Medical Center, Fort Walton, FL, USA; kDevelopment, Biodesix Inc., Louisville, CO, USA; lBiodesix Inc., Louisville, CO, USA; mThe Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; n Department of Medicine, Medical University of South Carolina, Charleston, SC, USA |  |  |\n| --- | --- | --- |\n| ABSTRACT\u003Cbr>Aim: To validate a blood-based autoantibody test (AAT) as a high specificity, rule-in biomarker for 4–30 mm indeterminate pulmonary nodules (IPN) across malignancy risk.\u003Cbr>Methods: Retrospective pooled analysis of four cohorts including adults with a 4–30 mm IPN, AAT result, and benign or malignant diagnosis. AAT results were classified as Moderate Level (all patients with elevated autoantibodies), High Level (stricter subset within Moderate Level), or No Significant Level of Autoantibodies Detected (NSLAD) . Post-test probability of cancer (pCA) was calculated by applying AAT likelihood ratios to pretest pCA. Performance was assessed overall, by nodule size, and risk strata. Results: Among 1164 patients (35% cancer prevalence), Moderate Level results showed sensitivity 16%, specificity 91%, and PPV 50% . A stricter subset of positives at the High Level, specificity 96%, and PPV 57%, with sensitivity 9% . When post-test pCA exceeded 65%, specificity was 97% and PPV 69%, while sensitivity was 12% . Performance was consistent across cohorts, nodule sizes, and risk strata, indicating size- and risk-independent discrimination. ~10% of intermediate-risk cancers (pretest 5–65%) were reclassified above the 65% threshold, creating a group with enriched malignancy risk.\u003Cbr>Conclusions: AAT provides size-and risk-independent, high-specificity rule-in performance, identifying subsets of patients whose malignancy risk may justify expedited evaluation. |  | ARTICLE HISTORY\u003Cbr>Received 16 December 2025 Accepted 30 January 2026\u003Cbr>KEYWORDS\u003Cbr>Autoantibody; blood-based biomarker; lung cancer; pulmonary nodule; risk reclassification |\n| 1. Introduction\u003Cbr>Risk stratification of indeterminate pulmonary nodules (IPN) is an increasing clinical challenge with the rising use of chest computed tomography (CT), leading to an estimated 1.6 million new nodules identified annually [1]. Previous studies have shown that approximately 31% of chest CT scans identify a lung nodule, with the probability of malignancy for these nodules spanning a broad, heterogeneous range dependent on factors like size, morphology, and patient characteristics (e.g., age, smoking history) [1,2]. Given their frequency and potential clinical significance, accurately riskstratifying IPNs across the size spectrum is critical for guiding appropriate follow-up and management strategies. In practice, referring all patients with pulmonary nodules for specialist evaluation or nodule clinic review is rarely feasible, and doi","cbCaigLBL9NJ6RsL","https://ap.wps.com/l/cbCaigLBL9NJ6RsL","pdf",3532899,12,"English","# Abstract\n# Introduction\n# Methods and Performance (retrospective pooled analysis)\n# Results\n## Diagnostic performance by AAT level and post-test probability\n## Consistency across cohorts and nodule sizes\n# Conclusions","[{\"question\":\"What does the study validate, and for which patients?\",\"answer\":\"The study validates a blood-based autoantibody test (AAT) for use as a high-specificity rule-in biomarker in adults with 4–30 mm indeterminate pulmonary nodules, across malignancy risk levels.\"},{\"question\":\"How are AAT results categorized and how is cancer risk updated?\",\"answer\":\"AAT results are classified into Moderate Level, High Level, and NSLAD. Post-test cancer probability is calculated by applying AAT likelihood ratios to pretest cancer probability.\"},{\"question\":\"What diagnostic performance did the AAT show overall and at higher post-test risk?\",\"answer\":\"Overall, Moderate Level results showed sensitivity 16%, specificity 91%, and PPV 50%. When post-test pCA exceeded 65%, specificity was 97% and PPV was 69%, with sensitivity 12%.\"}]","Validation of a blood-based autoantibody test to assess lung cancer risk in 4–30 mm pulmonary nodules - retrospective pooled analysis of four cohort studies | PDF",1790086455,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8cf8040a25a9e258170da2f7a4211f5.webp",983,1280,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/932b4c3aec187441e9671b4312b42623.webp",982,1278,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc3420c7b2963538b3a48a23288f89a8.webp",981,1277,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed480ebbedebb907c9497f1b2b5c802c.webp",980,1276]